Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Sahdeo (San Diego, United States of America), K. Taylor Meadows (San Diego, United States of America), S. Hoare (Owego, United States of America), T. Kenakin (Raleigh-Durham, United States of America), S. Murphy (San Diego, United States of America), T. Salter-Cid (San Diego, United States of America), H. Ortega (San Diego, United States of America), G. Opiteck (San Diego, United States of America), L. Salter-Cid (San Diego, United States of America), L. Carter (San Diego, United States of America). GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects. 1420

Member's Comments

No comment yet.

Related content which might interest you: In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist Source: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007 Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance Source: Annual Congress 2007 - New drugs for COPD Year: 2007 AZD3199: A potent and selective β2-adrenergic receptor agonist with rapid onset of action Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 The in vitro biology of Compound X – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407 Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007 Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Ligand independent activation of the glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2004; 24: Suppl. 48, 317s Year: 2004 Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 PKA/cAMP-independent transactivation of glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006 Preclinical safety profile of oral SCH 527123, a novel antagonist of CXCR2 Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007 AZD3199: A fast acting β2-receptor agonist with a long duration of action Source: Annual Congress 2011 - Translational models of disease Year: 2011 The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010 Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 The novel dual D2 dopamine receptor, β2-adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001 Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Effects of oral SCH 527123, a CXCR2 antagonist, on acquired immunity in healthy adults Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007 Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist Source: Annual Congress 2009 - New bronchodilators Year: 2009 Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001